Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Hauschild
A Phase II Trial of Tremelimumab (CP-675,206) in Patients With Advanced Refractory or Relapsed Melanoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
An Exploratory Study of Systemic Administration of the Toll-Like Receptor-7 Agonist 852A in Patients With Refractory Metastatic Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase I/Ii Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas
American Journal of Hematology
Hematology
Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers
Oncologist
Cancer Research
Medicine
Oncology
A Phase II Study of Docetaxel in Patients With Relapsed and Refractory Ewing's Tumours
Sarcoma
Nuclear Medicine
Radiology
Imaging
Oncology
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
Phase II Trial of Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer, With Assessment of Methylguanine-Dna Methyltransferase as a Potential Biomarker
Clinical Cancer Research
Cancer Research
Oncology
